Covid-19 Update — House of Commons, 2020-11-10
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I am very grateful to the hon. Member for his questions and for the approach that he is rightly taking. Like him, I am delighted that we are able to roll-out routine testing to NHS staff. That starts today. I am grateful to him for his support and I am grateful for the support and the urging of the Chair of the Health and Social Care Committee, my right hon. Friend the Member for South West Surrey (Jeremy Hunt) On contact tracing, we continue to work on the constant improvement needed, but, as the hon. Member said, the expansion of testing in a radical way because of the new technology that we have invested in and spent months working on, means that we will now be able to find more of the primary cases and more of the people who have the disease and then will be able to get them and their contacts to isolate. The single most important challenge is finding the people who have the virus in the first place The hon. Member mentioned children. The vaccine will not be used for children. It has not been tested on children. The reason is that the likelihood of children having significant detriment if they catch covid-19 is very, very low. This is an adult vaccine for the adult population He asked about the JCVI prioritisation. It is really important that we prioritise according to clinical risk. The JCVI has looked into all the risk factors, including ethnicity. It has concluded that age and whether a person works in health and social care are the two prime risk factors, which far outweigh any other, and so they are the primary risk factors that cascade into the draft interim prioritisation that it published on 25 September, which of course will be updated as it gets the final data that comes through from the clinical trials He asked about the proportion of the population that needs to be vaccinated. The honest truth to that question is that we do not know what proportion of the population the vaccination needs to reach in order for it to stop the epidemic. The reason we do not know that is that a clinical trial can check for the impact of the vaccine on protecting the individual—43,000 individuals, half of whom have had the vaccine. What cannot be checked is the impact on the transmission of the disease by those people, because a significant proportion of the population have to have had the vaccination to understand that. That is the difference between a so-called disease-modifying vaccine, which tests how much it affects the disease that an individual suffers if they get covid-19, versus an epidemic-modifying vaccine, which is about the impact on the spread and transmission of the disease. We cannot know that until after the vaccine has been rolled out, so we will monitor that very closely The hon. Gentleman asked about manufacture, which is important, and for this vaccine that is a matter for Pfizer. It is a difficult process. Distribution is also a huge challenge, and that is being led by the NHS. Because the vaccine must be stored at minus 70° until the final hours, the cold-chain requirements are significant and add to the logistical complications. However, we have known about that cold-chain requirement for many months, and it has been part of our planning for some time. We have a good degree of confidence that that will be in place. Finally, the hon. Gentleman asked about international collaboration. I am delighted that the UK has been a leader in efforts for international collaboration to find a vaccine. It has put in more money than any other nation, co-ordinating and bringing together scientists and vaccine specialists, and using our aid budget to ensure that people around the world get the vaccine in countries that, in some cases, could not afford to vaccinate their own population. We are a big part of the international work, and I very much look forward to working with colleagues in the United States, and everywhere else around the world, to ensure that we have a global vaccination programme as soon as a safe and effective set of vaccines can be made available.